https://mindmedicinelaw.com/briefing/rct-on-circular-breathwork-safety-in-trauma-affected-adults-20261008-48221The Psychedelic Journalen2026-10-09T15:08:03.205067+00:00RCT on Circular Breathwork Safety in Trauma-Affected Adultscircular breathwork, randomized controlled trial, adverse events, subclinical depression, childhood trauma, non-pharmacological interventions, psychotherapy safety, conscious connected breathwork, clinical integrationhttps://mindmedicinelaw.com/briefing/how-psychedelics-restructure-brain-information-flow-new-evidence-20261008-48189The Psychedelic Journalen2026-10-09T15:06:24.214542+00:00How Psychedelics Restructure Brain Information Flow: New Evidencepsychedelics, brain information flow, self-coupling, multivariate information decomposition, LSD, psilocybin, ketamine, DMT, clinical trial design, neural mechanismshttps://mindmedicinelaw.com/briefing/planned-psychedelic-trial-for-meth-use-disorder-in-hiv-patients-u-s-policy-and-c-20261008-48139The Psychedelic Journalen2026-10-08T22:04:26.507266+00:00Planned Psychedelic Trial for Meth Use Disorder in HIV+ Patients: U.S. Policy and Clinical Implicationsmethamphetamine use disorder, psychedelic clinical trial, hiv and addiction, fda policy, psychedelic-assisted therapy, public health, neuroplasticity, risk and ethics, addiction medicine, clinical researchhttps://mindmedicinelaw.com/briefing/filament-s-psilocybin-pex010-supply-deal-us-clinical-trial-implications-20261008-47964The Psychedelic Journalen2026-10-08T15:08:59.772047+00:00Filament's Psilocybin PEX010 Supply Deal: US Clinical Trial Implicationsfilament health, pex010, psilocybin supply, us clinical trials, fda compliance, gmp manufacturing, dea regulation, psychedelic research infrastructurehttps://mindmedicinelaw.com/briefing/fda-considers-ibogaine-trial-design-as-psychedelic-industry-eyes-commercializati-20261008-47961The Psychedelic Journalen2026-10-08T15:07:50.342274+00:00FDA Considers Ibogaine Trial Design as Psychedelic Industry Eyes Commercializationfda ibogaine trial design, psychedelic commercialization, compass pathways pricing, lsd brand names, psilocybin trademarks, psychedelic policy us, clinical trial safety, market access psychedelics, regulatory precedent, psychedelic therapy riskshttps://mindmedicinelaw.com/briefing/cooling-methods-for-drug-induced-hyperthermia-systematic-review-insights-for-eme-20261007-48210The Psychedelic Journalen2026-10-09T22:04:19.540472+00:00Cooling Methods for Drug-Induced Hyperthermia: Systematic Review Insights for Emergency Caredrug-induced hyperthermia, cooling methods, emergency medicine, psychedelic risk management, novel psychoactive substances, ice water immersion, pre-hospital protocols, systematic review, acute care, clinical guidelineshttps://mindmedicinelaw.com/briefing/italy-s-multi-indicator-surveillance-of-ats-and-synthetic-cathinones-20261007-48191The Psychedelic Journalen2026-10-09T15:09:34.167373+00:00Italy’s Multi-Indicator Surveillance of ATS and Synthetic Cathinonesitaly drug surveillance, amphetamine-type stimulants, synthetic cathinones, wastewater-based epidemiology, drug seizures, toxicological data, novel psychoactive substances, public health policy, regional drug trends, multi-indicator monitoringhttps://mindmedicinelaw.com/briefing/tianeptine-and-opioid-peptides-modulate-hippocampal-ampars-in-mice-20261007-48222The Psychedelic Journalen2026-10-09T15:09:11.795259+00:00Tianeptine and Opioid Peptides Modulate Hippocampal AMPARs in Micetianeptine, opioid peptides, ampar function, hippocampus, rapid-acting antidepressants, glutamatergic transmission, opioid receptor, abuse potential, psychiatric drug developmenthttps://mindmedicinelaw.com/briefing/durability-of-implanted-vagus-nerve-stimulation-in-us-trd-care-20261007-48230The Psychedelic Journalen2026-10-09T15:08:41.155552+00:00Durability of Implanted Vagus Nerve Stimulation in US TRD Carevagus nerve stimulation, treatment-resistant depression, RECOVER trial, neuromodulation, durability of response, mechanisms of action, psychedelic adjuncts, FDA approval, clinical guidelines, biomarkershttps://mindmedicinelaw.com/briefing/clearmind-s-fda-policy-submission-psychedelic-therapy-pathways-in-the-u-s-20261007-48308The Psychedelic Journalen2026-10-09T15:08:19.102012+00:00Clearmind's FDA Policy Submission: Psychedelic Therapy Pathways in the U.S.clearmind, fda, psychedelic therapy, drug development, policy recommendations, regulatory framework, clinical trials, industry engagement, us federal policyhttps://mindmedicinelaw.com/briefing/lsd-induced-brain-rhythm-changes-meg-study-advances-biomarker-research-20261007-48193The Psychedelic Journalen2026-10-09T15:07:44.185062+00:00LSD-Induced Brain Rhythm Changes: MEG Study Advances Biomarker Researchlsd, meg study, brain rhythms, neural complexity, psychedelic biomarkers, clinical trial design, spectral analysis, fractal dimension, neuroscience researchhttps://mindmedicinelaw.com/briefing/ketamine-for-ptsd-in-military-populations-systematic-review-insights-20261007-48232The Psychedelic Journalen2026-10-09T15:07:21.018452+00:00Ketamine for PTSD in Military Populations: Systematic Review Insightsketamine, ptsd, military veterans, systematic review, clinical trials, safety reporting, psychedelic research, treatment-resistant, policy implicationshttps://mindmedicinelaw.com/briefing/psychoactive-alkaloid-distribution-in-australian-acacia-policy-and-conservation--20261007-48243The Psychedelic Journalen2026-10-09T15:07:03.819594+00:00Psychoactive Alkaloid Distribution in Australian Acacia: Policy and Conservation Implicationsacacia alkaloids, dmt in plants, psychedelic plant policy, australian conservation, phytochemical profiling, multi-tissue analysis, endangered species, psychoactive compounds, drug law enforcement, sustainable harvestinghttps://mindmedicinelaw.com/briefing/va-launches-psilocybin-depression-study-for-u-s-veterans-20261007-48309The Psychedelic Journalen2026-10-09T15:06:44.398742+00:00VA Launches Psilocybin Depression Study for U.S. Veteransveterans affairs, psilocybin clinical trial, depression treatment, federal psychedelic research, mental health policy, veterans mental health, psychedelic-assisted therapy, clinical trial design, regulatory implicationshttps://mindmedicinelaw.com/briefing/expanding-u-s-psychedelic-policy-public-health-and-non-clinical-use-20261007-47839The Psychedelic Journalen2026-10-08T15:09:32.478134+00:00Expanding U.S. Psychedelic Policy: Public Health and Non-Clinical Usepsychedelic policy, public health, non-clinical use, us drug law, harm reduction, indigenous practices, mental health, historical context, regulatory frameworks, community accesshttps://mindmedicinelaw.com/briefing/clearmind-engages-fda-psychedelic-therapy-policy-in-focus-20261007-47962The Psychedelic Journalen2026-10-08T15:09:14.073531+00:00Clearmind Engages FDA: Psychedelic Therapy Policy in Focusclearmind, fda, psychedelic therapy, regulatory policy, industry submissions, clinical trials, us drug regulation, stakeholder engagement, drug development, public healthhttps://mindmedicinelaw.com/briefing/2r-6r-hnk-reverses-ptsd-like-behaviors-in-female-rats-20261007-47881The Psychedelic Journalen2026-10-08T15:08:24.229961+00:00(2R,6R)-HNK Reverses PTSD-like Behaviors in Female Rats2r6r-hydroxynorketamine, ptsd, blast injury, female veterans, preclinical research, glutamate signaling, animal models, neurobehavioral disorders, clinical translationhttps://mindmedicinelaw.com/briefing/systematic-review-ketamine-for-bpd-depression-and-suicidality-20261007-47880The Psychedelic Journalen2026-10-08T15:08:07.351964+00:00Systematic Review: Ketamine for BPD, Depression, and Suicidalityketamine, borderline personality disorder, bpd, systematic review, depression, suicidality, clinical trials, psychedelic research, safety, evidence gapshttps://mindmedicinelaw.com/briefing/usc-clinical-trial-explores-psilocybin-and-mindfulness-for-depression-20261007-47963The Psychedelic Journalen2026-10-08T15:06:47.238212+00:00USC Clinical Trial Explores Psilocybin and Mindfulness for Depressionpsilocybin, mindfulness meditation, depression, clinical trial, usc, keck school of medicine, psychedelic-assisted therapy, fda, mental health, combination therapyhttps://mindmedicinelaw.com/briefing/modern-antidepressants-and-psychedelic-mechanisms-clinical-and-policy-implicatio-20261006-47882The Psychedelic Journalen2026-10-08T22:05:03.678976+00:00Modern Antidepressants and Psychedelic Mechanisms: Clinical and Policy Implicationsmodern antidepressants, esketamine, glutamatergic mechanisms, neuroplasticity, psychedelic science, personalized psychiatry, clinical trial design, safety benchmarks, treatment-resistant depression, bdnfhttps://mindmedicinelaw.com/briefing/ego-dissolution-integration-framework-new-guidance-for-psychedelic-therapy-20261006-47841The Psychedelic Journalen2026-10-08T22:04:41.133338+00:00Ego Dissolution Integration Framework: New Guidance for Psychedelic Therapyego dissolution, psychedelic therapy, integration framework, clinical guidelines, predictive coding theory, acceptance and commitment therapy, internal family systems, interpersonal neurobiology, risk mitigation, therapist traininghttps://mindmedicinelaw.com/briefing/counselor-training-gaps-in-psychedelic-assisted-therapy-us-policy-and-practice-i-20261006-47840The Psychedelic Journalen2026-10-08T15:08:40.063527+00:00Counselor Training Gaps in Psychedelic-Assisted Therapy: US Policy and Practice Implicationspsychedelic-assisted therapy, counselor training, professional competencies, mental health policy, regulatory standards, public health risk, interdisciplinary collaboration, education gaps, clinical supervisionhttps://mindmedicinelaw.com/briefing/psychedelics-for-disorders-of-consciousness-u-s-neurotherapeutics-outlook-20261003-47903The Psychedelic Journalen2026-10-08T22:05:25.562088+00:00Psychedelics for Disorders of Consciousness: U.S. Neurotherapeutics Outlookpsychedelics, disorders of consciousness, neurotherapeutics, clinical trials, brain connectivity, FDA regulation, research ethics, serotonin 2A receptor, EEG complexity, NIH fundinghttps://mindmedicinelaw.com/briefing/novel-5-ht2a-agonists-patent-disclosure-signals-next-gen-psychedelic-therapeutic-20261002-47905The Psychedelic Journalen2026-10-08T22:05:42.689735+00:00Novel 5-HT2A Agonists: Patent Disclosure Signals Next-Gen Psychedelic Therapeutics5-ht2a agonists, psychedelic drug development, aminocyclohexenyl-6,6-bicyclic compounds, depression treatment research, anxiety therapeutics, substance use disorder, patent disclosure, clinical translation, regulatory pathways, novel psychoactive compoundshttps://mindmedicinelaw.com/briefing/ibogaine-induces-neural-repair-via-metabolic-preconditioning-in-mice-20261002-47907The Psychedelic Journalen2026-10-08T15:07:12.500550+00:00Ibogaine Induces Neural Repair via Metabolic Preconditioning in Miceibogaine, metabolic preconditioning, synaptic plasticity, neural repair, mitoKv1.3, sigma-2 receptor, preclinical study, psychedelic research, neuropsychiatric disorders, clinical trial designhttps://mindmedicinelaw.com/briefing/astrocytic-connexin-43-a-novel-target-in-parkinson-s-disease-pathology-20261001-47910The Psychedelic Journalen2026-10-08T22:05:59.837480+00:00Astrocytic Connexin 43: A Novel Target in Parkinson’s Disease Pathologyconnexin 43, astrocytes, parkinson's disease, neuroinflammation, glial targets, danegaptide, neuroplasticity, psychedelic therapeutics, clinical translation, gap junctionshttps://mindmedicinelaw.com/briefing/short-acting-tryptamines-clinical-evidence-and-regulatory-outlook-20261001-47857The Psychedelic Journalen2026-10-08T15:07:32.968046+00:00Short-Acting Tryptamines: Clinical Evidence and Regulatory Outlookshort-acting tryptamines, n,n-dmt, 5-meo-dmt, zalsupindole, treatment-resistant depression, phase 2b trial, neuroplasticity, hallucinogenic experience, regulatory strategy, adverse events